Delivery Order SPE2DB20D3111-SPE2DB25FA9GZ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count) under a firm fixed-price contract valued at $8,401.76, with an ultimate completion date of August 20, 2025. This non-set-aside competitive award was issued on August 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a contract value of $4,557.98. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a non-set-aside, competitively awarded procurement supporting federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $19,065.14 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed-price contract. The order was competitively awarded without set-aside provisions and is scheduled for completion by July 31, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $24,690.56 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitive award to the pharmaceutical distributor for delivery to the Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed-price contract valued at $2,392.21. The order carries an ultimate completion date of September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $28,942.08. This firm fixed-price delivery order, which is expected to be completed by August 25, 2025, was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company maintains operations as a...
- The Defense Logistics Agency awarded a delivery order valued at $3,514.43 to AmerisourceBergen Drug Corp for 60 tablets of Xifaxan 550 mg on August 13, 2025, with completion expected by August 14, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor,...
- The Defense Logistics Agency awarded a delivery order valued at $12,991.41 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on August 20, 2025, with completion scheduled for August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed price contract valued at $12,267.73. This non-set-aside competitive award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The ultimate completion date...
- The Defense Logistics Agency awarded a $6,885.33 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Xifaxan 550 mg on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitive award, which utilized firm fixed pricing with no set-aside designation, represents a pharmaceutical delivery under the company's existing contract vehicle with DLA. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- SPE2DB20D3111Indefinite Delivery Contract
- SPE2DB20D3111-SPE2DB25FA9GZDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xifaxan 550 mg tablets (60-count) valued at $10,828.02 under a firm fixed-price contract with an ultimate completion date of September 9, 2025. This non-competitive delivery order was issued without a set-aside designation, leveraging AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion prime vehicle running through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location. This delivery order represents a routine pharmaceutical supply transaction under AmerisourceBergen's comprehensive global pharmaceutical support agreement with the Defense Logistics Agency. As a major healthcare solutions provider to federal military and veteran healthcare systems, AmerisourceBergen has demonstrated capability to fulfill diverse medical procurement requirements ranging from brand-name and generic medications to specialized medical supplies. The company's role as a critical vendor within the DLA Medical Supply Chain ensures reliable delivery of pharmaceutical products to support military healthcare operations and readiness across the department's worldwide footprint.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.8k | 9/8/25 |